Shandong Sheelian Pharmaceutical Co Ltd, located in Heze, Shandong province, traces its roots back to 1983, when it commenced operations as an agricultural and related product processing enterprise. Over four decades of tireless efforts have transformed the company into a biopharmaceutical enterprise with a focus on manufacturing and developing heparin and ophthalmic drugs.

This area is part of the company's product research and development zone. [Photo/Dazhong News]

In 2009, the company embarked on a strategic expansion into the biopharmaceutical domain, venturing into the production and research of heparin-based products. Heparin, a widely used anticoagulant drug, plays a crucial role in the treatment of cardiovascular diseases and hemodialysis. Today, the company's position in the heparin market is firmly established, with its heparin sodium product holding an 85 percent share in the domestic market.

In 2016, it further expanded its pharmaceutical portfolio to encompass ophthalmic medications, and broadened its research scope to cover a comprehensive range of eye care products, including eye examination, mydriasis, allergy, dry eye syndrome, glaucoma, myopia, and amblyopia. Simultaneously, the company actively recruited a team of industry-leading talent and forged comprehensive partnerships with key domestic universities and research institutes.

Presently, the company's product portfolio primarily comprises heparin and ophthalmic drugs. It has successfully obtained five drug registration numbers, with four drugs currently undergoing review and 12 products in the research pipeline.